Patritumab Deruxtecan Demonstrated Statistically Significant
WEB4 days ago · Patritumab deruxtecan is a specifically engineered potential first-in-class HER3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed by Daiichi Sankyo and Merck (NYSE: MRK), known as MSD outside of the United States and Canada.
Patritumab Deruxtecan Demonstrated Statistically Significant ...
WEB4 days ago · The HERTHENA-Lung02 phase 3 trial evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who received prior EGFR tyrosine kinase inhibitor (TKI) treatment met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant improvement ...
Patritumab Deruxtecan Meets PFS End Point in Pretreated EGFR …
WEB3 days ago · The HERTHENA-Lung02 trial met its primary end point of improved PFS with patritumab deruxtecan in pretreated EGFR-mutated non–small cell lung cancer.
Patritumab deruxtecan extends PFS vs. chemotherapy in …
WEB3 days ago · Patritumab deruxtecan improved PFS compared with chemotherapy among certain patients with advanced non-small cell lung cancer, according to the agent’s manufacturer.
Patritumab Deruxtecan Granted Priority Review in the U.S. for
WEBDec 22, 2023 · Patritumab deruxtecan was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration in December 2021 for the treatment of patients with EGFR-mutated locally advanced or metastatic NSCLC with disease progression on or after treatment with a third-generation TKI and platinum-based therapies.
Patritumab Deruxtecan BLA Submission Receives Complete …
WEBJun 26, 2024 · patritumab deruxtecan in patients with EGFR-mutated locally advanced or metastatic NSCLC following disease progression with an EGFR TKI and platinum-based chemotherapy. Patients were randomized 1:1 to receive 5.6 mg/kg
Patritumab Deruxtecan Demonstrated Clinically Meaningful and …
WEBSep 10, 2023 · Patritumab deruxtecan was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration in December 2021 for the treatment of patients with EGFR-mutated locally advanced or metastatic NSCLC with disease progression on or after treatment with a third-generation TKI and platinum-based therapies.
Patritumab Deruxtecan Demonstrates a Manageable Safety …
WEBOct 19, 2023 · Patritumab deruxtecan is a novel, first-in-class, HER3-directed antibody drug conjugate (ADC). In HER3-expressing xenograft models, patritumab deruxtecan demonstrated antitumour responses across a range of baseline HER3 expression levels that were sustained over time.
Patritumab Deruxtecan Granted U.S. FDA Breakthrough Therapy …
WEBDec 23, 2021 · The global, multicenter, open label, two-part phase 1 study is evaluating patritumab deruxtecan in previously treated patients with metastatic or unresectable NSCLC.
Patritumab Deruxtecan Active in HER3-Expressing ... - ASCO Daily News
WEBJun 4, 2022 · The HER3-directed antibody-drug conjugate (ADC) patritumab deruxtecan is active in patients with heavily pretreated HER3-expressing metastatic breast cancer, according to results of a phase 1/2 study.
- Some results have been removed